Pomalidomide

Pomalidomide (INN; marketed as Pomalyst in the US[3] and Imnovid in the European Union and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator.[medical citation needed] Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.[6] It has been approved for use in people who have received at ... [wikipedia]